Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT BSE: 524742 SECTOR: Pharmaceuticals & Drugs  132k   1k   200

777.40
+3.25 (0.42%)
NSE: Today, 03:57 PM

Price Summary

Today's High

₹ 781.8

Today's Low

₹ 774.3

52 Week High

₹ 856.8

52 Week Low

₹ 575

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5903.09 Cr.

Enterprise Value

5587.01 Cr.

No. of Shares

7.59 Cr.

P/E

25.2

P/B

5.18

Face Value

₹ 2

Div. Yield

0.26 %

Book Value (TTM)

₹  150.12

CASH

316.08 Cr.

DEBT

0 Cr.

Promoter Holding

70.66 %

EPS (TTM)

₹  30.85

Sales Growth

9.4%

ROE

22.56 %

ROCE

29.64%

Profit Growth

20.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.4%
3 Year-0.55%
5 Year9.11%

Profit Growth

1 Year20.25%
3 Year8.24%
5 Year21.72%

ROE%

1 Year22.56%
3 Year28.3%
5 Year33.55%

ROCE %

1 Year29.64%
3 Year36.54%
5 Year44.87%

Debt/Equity

0

Price to Cash Flow

25.56

Interest Cover Ratio

2782.22222222222

CFO/PAT (5 Yr. Avg.)

0.937328826649402

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 70.66 0
Dec 2022 68.8 0
Sep 2022 68.88 0
Jun 2022 68.88 0
Mar 2022 68.89 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.01 Cr.
  • Company has been maintaining healthy ROE of 28.2981833621602% over the past 3 years.
  • Company has been maintaining healthy ROCE of 36.5411358263999% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 2782.22222222222.
  • The Company has been maintaining an effective average operating margins of 38.5329830832745% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -50.9726887655994 days.
  • Company has a healthy liquidity position with current ratio of 6.12530339805825.
  • The company has a high promoter holding of 70.66%.

 Limitations

  • The company has shown a poor profit growth of 8.23535296797815% for the Past 3 years.
  • The company has shown a poor revenue growth of -0.552221628389193% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 111.94 116.39 136.95 130.6 144.67
Total Expenditure 73.53 70.28 79.53 79.09 79.8
Operating Profit 38.41 46.11 57.42 51.51 64.87
Other Income 10.26 34.97 22.45 29.36 12.22
Interest 0.02 0.01 0.04 0.04 0.03
Depreciation 6.95 6.37 6.51 6.47 6.29
Exceptional Items 0 0 0 0 0
Profit Before Tax 41.7 74.7 73.32 74.36 70.77
Tax 12.68 11.46 15.81 15.19 16.44
Profit After Tax 29.02 63.24 57.51 59.17 54.33
Adjusted EPS (Rs) 3.83 8.34 7.59 7.8 7.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 426.57 536.91 527.83 482.68 528.06
Total Expenditure 284.33 348.31 320.83 273.14 308.58
Operating Profit 142.25 188.6 206.99 209.54 219.48
Other Income 23.31 35.4 65.97 23.01 56.69
Interest 0.52 0.5 0.19 0.17 0.09
Depreciation 18.99 20.84 19.65 22.44 25.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 146.05 202.65 253.12 209.94 250.31
Tax 43.74 54.49 55.49 53.71 62.44
Net Profit 102.31 148.17 197.64 156.23 187.87
Adjusted EPS (Rs.) 13.53 19.59 26.13 20.65 24.79

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 15.12 15.13 15.13 15.13 15.16
Total Reserves 280.48 416.92 584.78 743.54 915.49
Borrowings 0.32 0.29 0.02 0 0
Other N/C liabilities 27.54 24.48 27.15 24.99 24.63
Current liabilities 87.34 82.51 64.26 77.33 98.88
Total Liabilities 410.8 539.33 691.33 860.99 1054.16
Assets
Net Block 169.32 137.77 166.93 182.68 162.46
Capital WIP 15.29 8.62 3.77 1.36 1.73
Intangible WIP 0 0 0 0 0.87
Investments 1.87 98.62 135.54 138.64 212.73
Loans & Advances 11.11 6.36 4.36 5.67 70.7
Other N/C Assets 0 0 0 20 0
Current Assets 213.21 287.95 380.74 512.64 605.67
Total Assets 410.8 539.33 691.33 860.99 1054.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 146.05 202.65 253.12 209.94 250.31
Adjustment 3.44 -0.29 -32.58 7.75 -19.43
Changes in Assets & Liabilities -92.59 -54.17 -83.19 131.85 62.07
Tax Paid -34.29 -40.84 -50.35 -54.9 -61.98
Operating Cash Flow 22.61 107.34 87.01 294.64 230.97
Investing Cash Flow -59.72 -75.79 -41 -3.9 -237.27
Financing Cash Flow -11.6 -15.21 -32.92 -3.47 -22.76
Net Cash Flow -48.71 16.34 13.09 287.27 -29.06

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 68.89 68.88 68.88 68.80 70.66
p vijayalakshmi - - - 23.59 23.56
p vijayalakshmi 23.60 23.59 23.59 - -
p vijayalakhsmi - - - - -
paarthipan c c 18.70 18.69 18.69 18.69 18.67
paarthipan c c - - - - -
ashok gorkey parth... 11.94 11.94 11.94 11.94 11.92
ashok gorkey par... - - - - -
partheeban vivek ... - - - - -
partheeban vivek s... 11.88 11.88 11.87 11.87 11.86
partheeban vivek ... - - - - -
may india propert... - - - - -
may india property... 2.79 2.79 2.79 2.79 2.79
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 31.11 31.12 31.12 31.20 29.34
matthews india fu... - - - - -
iepf 2.45 2.44 2.55 - -
visalatchi 1.26 1.26 1.25 1.25 1.25
investor education... - - - 2.53 2.52
suresh kumar agarw... 1.32 1.32 1.32 1.32 1.32
suresh kumar agar... - - - - -
ashish kacholia - - - - -
llp 0.82 0.81 0.81 0.48 0.48
margin trading acc... - - - 0.01 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

USFDA completes inspection at Sterile Injectable site of Caplin Point Laboratories’ arm1 Jun 2023, 11:53AM Caplin Point Laboratories informs about outcome of board meeting27 May 2023, 2:20PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Laboratories informs about press release12 May 2023, 2:55PM Caplin Point Laboratories’ arm gets USFDA’s nod for Ketorolac Tromethamine Injection12 May 2023, 11:57AM Caplin Point to sell Caplin Point Laboratories Colombia SAS to Caplin Point Far East29 Mar 2023, 6:10PM Caplin Point Laboratories’ arm gets USFDA’s nod for Thiamine Hydrochloride Injection8 Mar 2023, 2:47PM Caplin Point Laboratories informs about press release8 Mar 2023, 12:07PM Caplin Point Laboratories informs about press release3 Mar 2023, 3:04PM Caplin Point Laboratories’ arm gets USFDA’s approval for Rocuronium Bromide Injection3 Mar 2023, 12:39PM Caplin Point Laboratories informs about loss of share certificate 27 Feb 2023, 3:50PM Caplin Point Laboratories’ arm gets USFDA’s final approval for Carboprost Tromethamine Injection14 Feb 2023, 1:06PM Caplin Point Lab - Quaterly Results11 Feb 2023, 1:28PM Caplin Point Lab - Quaterly Results11 Feb 2023, 1:28PM Caplin Point Lab - Quaterly Results11 Feb 2023, 1:28PM Caplin Point Laboratories informs about loss of share certificate 12 Jan 2023, 4:47PM Caplin Point Laboratories informs about details of loss of certificate 22 Dec 2022, 2:41PM Caplin Point Laboratories informs about allotment of ESOP 15 Dec 2022, 4:52PM Caplin Point Lab - Quaterly Results12 Nov 2022, 1:46PM Caplin Point Lab - Quaterly Results12 Nov 2022, 1:46PM Caplin Point Lab - Quaterly Results12 Nov 2022, 1:46PM Caplin Point Laboratories informs about loss of share certificate 12 Sep 2022, 4:33PM Caplin Point laboratories informs about loss of share certificate 22 Aug 2022, 4:51PM Caplin Point selected under Forbes Asia’s ‘200 best under billion list’ 22 Aug 2022, 4:24PM Caplin Point Laboratories informs about press release22 Aug 2022, 10:37AM Caplin Point Laboratories informs about audio recording 8 Aug 2022, 12:44PM Caplin Point Lab - Quaterly Results5 Aug 2022, 1:06PM Caplin Point Lab - Quaterly Results5 Aug 2022, 1:06PM Caplin Point Lab - Quaterly Results5 Aug 2022, 1:06PM Caplin Point laboratories informs about resignation of director12 Jul 2022, 10:40AM Caplin Point Laboratories informs about resignation of CS cum CO25 Jun 2022, 3:09PM Caplin Point Laboratories informs about allotment of equity shares on exercise of ESOPs12 May 2022, 3:54PM Caplin Point Lab - Quaterly Results12 May 2022, 1:03PM Caplin Point Lab - Quaterly Results12 May 2022, 1:03PM Caplin Point Lab - Quaterly Results12 May 2022, 1:03PM Caplin Point Laboratories informs about board meeting5 May 2022, 5:24PM Caplin Point Laboratories informs about board meeting5 May 2022, 4:45PM Caplin Point Laboratories informs about certificate6 Apr 2022, 10:25AM Caplin Point Laboratories informs about compliance certificate4 Apr 2022, 11:51AM Caplin Point Lab - Quaterly Results3 Feb 2022, 1:02PM Caplin Point Lab - Quaterly Results3 Feb 2022, 1:02PM Caplin Point Lab - Quaterly Results3 Feb 2022, 1:02PM Caplin Point Laboratories informs about board meeting28 Jan 2022, 12:08PM Caplin Point Laboratories informs about loss of share certificate27 Jan 2022, 2:48PM Caplin Point Laboratories informs about details of loss of share certificate 20 Nov 2021, 2:52PM Caplin Point Lab - Quaterly Results2 Nov 2021, 12:56PM Caplin Point Laboratories informs about loss of share certificate21 Oct 2021, 10:39AM Caplin Point Laboratories informs about press release 24 Sep 2021, 3:12PM

Caplin Point Lab Stock Price Analysis and Quick Research Report. Is Caplin Point Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Caplin Point Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 230.97 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Caplin Point Lab has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Caplin Point Lab , the EPS growth was 20.0143329604827 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Caplin Point Lab has OPM of 41.5634586978752 % which is a good sign for profitability.
     
  • ROE: Caplin Point Lab have a healthy ROE of 22.5592439825405 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Caplin Point Lab

X